Navigating China's Healthcare Compliance Landscape: New Guidelines to Mitigate Commercial Bribery Risks
By EsqSocial Corporation 23/12/24
China's State Administration for Market Regulation (SAMR) has released the draft Compliance Guidelines for Healthcare Companies to Prevent Commercial Bribery Risks (Draft Guidelines) for public comment. The Draft Guidelines, issued on October 11, 2024, set out the regulator's expectation on how pharmaceutical and medical device companies operating in China may reduce or prevent commercial bribery risks....
By: DLA Piper